235 related articles for article (PubMed ID: 31873172)
1. Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone.
Isfort I; Elges S; Cyra M; Berthold R; Renner M; Mechtersheimer G; Åman P; Larsson O; Ratner N; Hafner S; Simmet T; Schliemann C; Rossig C; Dirksen U; Grünewald I; Wardelmann E; Huss S; Hartmann W; Trautmann M
Sci Rep; 2019 Dec; 9(1):19704. PubMed ID: 31873172
[TBL] [Abstract][Full Text] [Related]
2. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
3. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
[TBL] [Abstract][Full Text] [Related]
5. The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis.
Kovar H; Bierbaumer L; Radic-Sarikas B
Cells; 2020 Apr; 9(4):. PubMed ID: 32326412
[TBL] [Abstract][Full Text] [Related]
6. Hippo-YAP1 signaling pathway and severe preeclampsia (sPE) in the Chinese population.
Liu R; Wei C; Ma Q; Wang W
Pregnancy Hypertens; 2020 Jan; 19():1-10. PubMed ID: 31841877
[TBL] [Abstract][Full Text] [Related]
7. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
8. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
[TBL] [Abstract][Full Text] [Related]
9. Requirement for YAP1 signaling in myxoid liposarcoma.
Trautmann M; Cheng YY; Jensen P; Azoitei N; Brunner I; Hüllein J; Slabicki M; Isfort I; Cyra M; Berthold R; Wardelmann E; Huss S; Altvater B; Rossig C; Hafner S; Simmet T; Ståhlberg A; Åman P; Zenz T; Lange U; Kindler T; Scholl C; Hartmann W; Fröhling S
EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 30898787
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation.
Sato H; Hasegawa T; Abe Y; Sakai H; Hirohashi S
Hum Pathol; 1999 Nov; 30(11):1344-9. PubMed ID: 10571515
[TBL] [Abstract][Full Text] [Related]
11. YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Ye S; Lawlor MA; Rivera-Reyes A; Egolf S; Chor S; Pak K; Ciotti GE; Lee AC; Marino GE; Shah J; Niedzwicki D; Weber K; Park PMC; Alam MZ; Grazioli A; Haldar M; Xu M; Perry JA; Qi J; Eisinger-Mathason TSK
Cancer Res; 2018 May; 78(10):2705-2720. PubMed ID: 29490948
[TBL] [Abstract][Full Text] [Related]
12. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
Nagashima S; Bao Y; Hata Y
Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
[TBL] [Abstract][Full Text] [Related]
13. Targeting YAP1/TAZ in nonsmall-cell lung carcinoma: From molecular mechanisms to precision medicine.
Mui CW; Chan WN; Chen B; Cheung AH; Yu J; Lo KW; Ke H; Kang W; To KF
Int J Cancer; 2023 Feb; 152(4):558-571. PubMed ID: 35983734
[TBL] [Abstract][Full Text] [Related]
14. Loss of
Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A
Development; 2018 Mar; 145(6):. PubMed ID: 29511023
[TBL] [Abstract][Full Text] [Related]
15. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.
Yuan Y; Park J; Feng A; Awasthi P; Wang Z; Chen Q; Iglesias-Bartolome R
Nat Commun; 2020 Mar; 11(1):1472. PubMed ID: 32193376
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
[TBL] [Abstract][Full Text] [Related]
17. Glucose promotes epithelial-mesenchymal transitions in bladder cancer by regulating the functions of YAP1 and TAZ.
Li S; Zhu H; Chen H; Xia J; Zhang F; Xu R; Lin Q
J Cell Mol Med; 2020 Sep; 24(18):10391-10401. PubMed ID: 32678516
[TBL] [Abstract][Full Text] [Related]
18. Alantolactone is a natural product that potently inhibits YAP1/TAZ through promotion of reactive oxygen species accumulation.
Nakatani K; Maehama T; Nishio M; Otani J; Yamaguchi K; Fukumoto M; Hikasa H; Hagiwara S; Nishina H; Mak TW; Honma T; Kondoh Y; Osada H; Yoshida M; Suzuki A
Cancer Sci; 2021 Oct; 112(10):4303-4316. PubMed ID: 34289205
[TBL] [Abstract][Full Text] [Related]
19. Grb2-associated binding protein-1 as a biomarker in bone and soft tissue sarcomas.
Al-Husseinawi E; Bui MM; Ahmed AA
Pathology; 2019 Oct; 51(6):610-614. PubMed ID: 31443923
[TBL] [Abstract][Full Text] [Related]
20. Differential influence of YAP1 and TAZ on differentiation of intestinal epithelial cell: A review.
Fallah S; Beaulieu JF
Anat Rec (Hoboken); 2023 May; 306(5):1054-1061. PubMed ID: 35648375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
